Skip to main content
. 2022 Oct 15;14(10):6856–6873.

Figure 7.

Figure 7

miR-382-3p targeted BTRC mRNA. (A) Possible target mRNAs of miR-382-3p predicted using several bioinformatic systems; (B) Expressions of the candidate mRNAs in endothelial progenitor cells after miR-382-3p mimic transfection examined by RT-qPCR; (C) mRNA expression of BTRC in the murine lung, kidney and liver tissues examined by RT-qPCR; (D) Putative binding site between BTRC and miR-382-3p and the WT sequence prepared for luciferase assay; (E) Luciferase activity of the BTRC-WT and the BTRC-MT luciferase reporter vectors examined by the dual luciferase reporter gene assay. In each group in (C), n = 6. Differences in (B, C and E) were analyzed by two-way ANOVA and Tukey’s multiple comparison. *P < 0.05 vs. the sham group, #P < 0.05 vs. the CLP group, &P < 0.05 vs. the CLP group. BTRC, beta-transducin repeat containing E3 ubiquitin protein ligase; WT, wild type; MT, mutant type.